RGD‐modified anti‐CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward αvβ3‐expressing endothelial cells
Open Access
- 17 August 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 112 (2) , 279-285
Abstract
To redirect the lytic activity of cytotoxic T lymphocytes (CTL) toward tumor vascular endothelial cells, we prepared bifunctional proteins with specificity for both αvβ3 and CD3. Monocyclic RGD peptides (cRGDfK) were covalently coupled to an anti‐CD3 monoclonal antibody at different peptide:protein ratios. The resulting RGDpep‐anti‐CD3 conjugates bound specifically to αvβ3‐expressing endothelial cells. Displacement studies with radiolabeled αvβ3 ligand demonstrated that the αvβ3 binding affinity of RGDpep‐anti‐CD3 conjugates was elevated as compared to the non‐conjugated RGDpep. IC50 values ranged from 150–1.1 nM, depending on the amount of coupled RGDpep molecules per antibody molecule. RGD modification did not affect the ability of anti‐CD3 antibodies to bind to CTL. Furthermore, RGDpep‐anti‐CD3 was fully capable of activating T cells upon CD3 binding as was shown in a Jurkat/NFAT reporter‐gene activation assay. All RGDpep‐anti‐CD3 conjugates were able to induce RGDpep, CD3‐dependent lysis of human primary endothelial cells by anti‐CD3/IL‐2 activated human peripheral blood mononuclear cells (PBMC), with a significant induction of cytotoxicity observed at an E/T ratio as low as 10. Redirecting cytolytic activity reached up to 50% cytotoxicity using the conjugate with the highest RGD peptide load. Combining the good accessibility of tumor blood vessel endothelium for CTL with the efficiency of target cell killing warrants further investigations on anti‐tumor effects of this type of conjugates in vivo.Keywords
This publication has 21 references indexed in Scilit:
- Optimizing anti-CD3 affinity for effective T cell targeting against tumor cellsEuropean Journal of Immunology, 2002
- Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution studyInternational Journal of Cancer, 2002
- Tumor Regression by Targeted Gene Delivery to the NeovasculatureScience, 2002
- Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and MetastasisJournal of Experimental Medicine, 2002
- Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptorsProceedings of the National Academy of Sciences, 2002
- IMMUNOGENE THERAPY OF TUMORS WITH A VACCINE BASED ON THE LIGAND-BINDING DOMAIN OF CHICKEN HOMOLOGOUS INTEGRINβ3Immunological Investigations, 2002
- Immunotherapy of tumors with xenogeneic endothelial cells as a vaccineNature Medicine, 2000
- Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed IntegrinsNature Biotechnology, 1995
- Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cellsNature, 1983
- Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific ActivityNature, 1962